CO-1686

Known as: EGFR Inhibitor CO-1686 
An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
051020112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
PURPOSE The evaluation of plasma testing for the EGFR resistance mutation T790M in NSCLC patients has not been broadly explored… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
PURPOSE Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
PURPOSE To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is… (More)
  • figure 1
Is this relevant?
2015
2015
PURPOSE Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are… (More)
Is this relevant?
2015
2015
Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary… (More)
Is this relevant?
2014
2014
Patients with non–small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2014
2014
Approximately 4 to 15% of lung adenocarcinomas harbor a genomic rearrangement in the anaplastic lymphoma kinase gene (ALK) that… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
UNLABELLED Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to… (More)
  • table 1
  • table 2
Is this relevant?
2013
2013
EGFR mutations identify patients who are more likely to respond to treatment with epidermal growth factor receptor (EGFR… (More)
Is this relevant?